Sugi Predict

Sugi Predict / Targets / MGMT

MGMT

Methylated-DNA--protein-cysteine methyltransferase · P16455 · MGMT on Sugi Atlas →

4,515 patent compounds predicted against MGMT, 1,828 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3309544 SCHEMBL3309544 1.00 13/20
SCHEMBL4068099 SCHEMBL4068099 0.76 12/20
SCHEMBL6362726 SCHEMBL6362726 0.63 11/20
SCHEMBL2054835 SCHEMBL2054835 1.00 10/20
Lomeguatrib Lomeguatrib (SCHEMBL4621691) 1.00 10/20
SCHEMBL3338895 SCHEMBL3338895 0.76 10/20
SCHEMBL2930276 SCHEMBL2930276 0.62 10/20
SCHEMBL5930450 SCHEMBL5930450 0.58 10/20
6-O-Benzylguanine 6-O-Benzylguanine (SCHEMBL61740) 1.00 9/20
SCHEMBL6265081 SCHEMBL6265081 1.00 9/20
SCHEMBL6270250 SCHEMBL6270250 1.00 9/20
6-O-Benzylguanine 6-O-Benzylguanine (SCHEMBL4631744) 0.97 9/20
SCHEMBL3300787 SCHEMBL3300787 0.76 9/20
SCHEMBL6265344 SCHEMBL6265344 0.74 9/20
SCHEMBL3338311 SCHEMBL3338311 0.68 9/20
SCHEMBL6270230 SCHEMBL6270230 0.67 9/20
SCHEMBL6358672 SCHEMBL6358672 0.66 9/20
SCHEMBL5039831 SCHEMBL5039831 0.65 9/20
SCHEMBL311200 SCHEMBL311200 0.64 9/20
SCHEMBL3425790 SCHEMBL3425790 0.62 9/20

Clinical trials — most relevant to MGMT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma PHASE3COMPLETED
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme PHASE3COMPLETED
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients PHASE2COMPLETED
Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy PHASE2UNKNOWN
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer PHASE2COMPLETED
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting PHASE2COMPLETED
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) PHASE2NOT_YET_RECRUITING
Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC PHASE2COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma PHASE1/PHASE2NOT_YET_RECRUITING
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer PHASE2RECRUITING
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. PHASE1/PHASE2RECRUITING
Temozolomide in Treating Patients With Recurrent High-Grade Glioma PHASE2COMPLETED
Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma PHASE2COMPLETED
A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas PHASE2UNKNOWN
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) PHASE1/PHASE2UNKNOWN
Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma PHASE2UNKNOWN
Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma PHASE2COMPLETED
Prolonged Adjuvant Temozolomide vs Stop & Go in Glioblastoma Patients PHASE2UNKNOWN
TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT PHASE2UNKNOWN
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme PHASE2ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients PHASE1/PHASE2RECRUITING
Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma PHASE2ACTIVE_NOT_RECRUITING
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM PHASE1ACTIVE_NOT_RECRUITING
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer PHASE1COMPLETED
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM PHASE1ACTIVE_NOT_RECRUITING
D2C7-IT + 2141-V11 Combination Post-resection in rGBM PHASE1RECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Serum DNA Analysis: Potential Application for Diagnosis and Prognosis in Brain Cancer. nanUNKNOWN
6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM) nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a MGMT binder may also engage these)

ProteinNameSimilarity
Q6TDU1 — 0.998 Q6TDU1 →
P26187 — 0.996 P26187 →
P24528 — 0.993 P24528 →
P26186 — 0.989 P26186 →
A5E7M8 — 0.987 A5E7M8 →
A6ZXD3 — 0.981 A6ZXD3 →
P26188 — 0.979 P26188 →
B7NR48 — 0.979 B7NR48 →
P0A2U1 — 0.978 P0A2U1 →
P0A2U0 — 0.978 P0A2U0 →
Q9FAB3 — 0.978 Q9FAB3 →
P0AFH1 — 0.978 P0AFH1 →
P0AFH0 — 0.978 P0AFH0 →
Q7MYT9 — 0.978 Q7MYT9 →
Q5RDS0 — 0.978 Q5RDS0 →
Q6AY47 — 0.977 Q6AY47 →
Q9D5Z5 — 0.977 Q9D5Z5 →
Q6ZV29 — 0.977 Q6ZV29 →
KDM1A Lysine-specific histone demethylase 1A 0.977 landscape →
B7UML1 — 0.977 B7UML1 →
B5YY04 — 0.977 B5YY04 →
Q4VC12 — 0.977 Q4VC12 →
Q8BIX9 — 0.976 Q8BIX9 →
P40594 — 0.976 P40594 →
Q1QYV9 — 0.976 Q1QYV9 →
Q7TNB8 — 0.976 Q7TNB8 →
P44687 — 0.976 P44687 →
A3KMV1 — 0.976 A3KMV1 →
Q31P08 — 0.976 Q31P08 →
Q05AS3 — 0.976 Q05AS3 →